Latest Headlines

  1. IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline 11/3/2025

    IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced an expansion of its AI-powered in-Silico drug discovery platform.

  2. Nuclera Expands Access To eProtein Discovery For APAC Customers With Distributor Agreement In Australia And New Zealand 11/3/2025

    Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery System, today announced that it has signed a partnership with Solve Scientific Australia, a life science research solutions provider.

  3. Manifold Bio Announces Strategic Collaboration With Roche To Develop Multiple Next-Generation Brain Shuttles For Neurological Diseases 11/3/2025

    Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration and license agreement with Roche.

  4. Debiopharm Forges AI-powered Alliance With NetTargets To Pioneer Dual-Payload ADCs Against Drug-Resistant Cancers 10/30/2025

    Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs).

  5. Foundation Medicine And Manifold Partner To Accelerate Drug Discovery And Development By Bringing AI-Enabled Analytics To FoundationInsights 10/30/2025

    Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced a partnership with Manifold, the leading artificial intelligence (AI) data platform for life sciences, to bring enhanced AI capabilities to FoundationInsights, a cloud-based data analytics and visualization platform that derives insights from Foundation Medicine’s proprietary multimodal datasets.

  6. Lantern Pharma To Present AI-Driven Cancer Drug Development & Research Platforms At Inaugural AI For Biology And Medicine Symposium At UNT 10/30/2025

    Lantern Pharma Inc. — Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas.

  7. Amneal Receives U.S. FDA Tentative Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol 10/29/2025

    Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has tentatively approved the Company’s Abbreviated New Drug Application (ANDA) for beclomethasone dipropionate HFA inhalation aerosol (40 mcg/actuation and 80 mcg/actuation). 

  8. Ace Therapeutics Advances Analgesic Drug Discovery Through Specialized Preclinical Services 10/29/2025

    Ace Therapeutics, a comprehensive preclinical contract research organization, today highlighted its specialized suite of services designed to accelerate the discovery and development of next-generation analgesic drugs.

  9. AI-Designed Drug AH-001 Complete U.S. Phase I Trial, Demonstrating Excellent Safety And Tolerability 10/29/2025

    AnHorn Medicines, a biotech company leveraging generative AI to design small molecules and protein degraders, today announced positive results from its U.S. Phase I clinical trial of AH-001, an AI-generated topical protein degrader developed for the treatment of androgenetic alopecia (male pattern hair loss).

  10. FDA Grants Orphan Drug Designation To Dewpoint Therapeutics' DPTX3186 For The Treatment Of Gastric Cancer 10/29/2025

    Dewpoint Therapeutics, the leader in condensate biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the treatment of gastric cancer.